SCHEMBL19645667

SCHEMBL19645667

Cc1ccc(S(=O)(=O)C#CCc2ncccn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
SMN1; SMN2 Q16637 5/20 0.43
HTT P42858 4/20 0.43
KMT2A Q03164 4/20 0.41
LMNA P02545 6/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PTGS2 P35354 1/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.40
CKS1B P61024 2/20 0.40
SKP2 Q13309 2/20 0.40
MEN1 O00255 2/20 0.40
MITF O75030 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
AGTR1 P30556 1/20 0.40
OPRK1 P41145 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SLC40A1 Q9NP59 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9770800 0.74 GAA (0.46) ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL28577615 0.73 GAA (0.59) ALDH1A1SMN1; SMN2KMT2ATDP1MAPT
SCHEMBL18495722 0.71 CA2 (0.44) ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5865439 0.70 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL2499107 0.69 GAA (0.48) ALDH1A1SMN1; SMN2KMT2ATDP1MAPT
SCHEMBL12306892 0.68 ALDH1A1 (0.87) ALDH1A1SMN1; SMN2HTTKMT2ALMNA
SCHEMBL13783355 0.68 GAA (0.52) ALDH1A1SMN1; SMN2KMT2ATDP1MAPT
SCHEMBL2493552 0.66 GAA (0.50) ALDH1A1SMN1; SMN2KMT2ATDP1MAPT
SCHEMBL6547519 0.66 GAA (0.50) ALDH1A1SMN1; SMN2KMT2ATDP1MAPT
SCHEMBL28433392 0.65 CA2 (0.60) ALDH1A1SMN1; SMN2HTTTDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828396-B2 Alkyne compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-11-28 US disclosed